HLS Therapeutics Inc (TO:HLS) — Market Cap & Net Worth
Market Cap & Net Worth: HLS Therapeutics Inc (HLS)
HLS Therapeutics Inc (TO:HLS) has a market capitalization of $92.53 Million (CA$127.91 Million) as of September 17, 2026. Listed on the TO stock exchange, this Canada-based company holds position #19557 globally and #653 in its home market, demonstrating a 10.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HLS Therapeutics Inc's stock price CA$4.09 by its total outstanding shares 31273681 (31.27 Million). Also see HLS Therapeutics Inc asset portfolio for a full breakdown of the balance sheet.
HLS Therapeutics Inc Market Cap History: 2015 to 2026
HLS Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $52.82 Million to $92.53 Million (5.16% CAGR). Also see how efficiently does HLS Therapeutics Inc generate cash for how efficiently the company converts equity into cash flow.
HLS Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HLS Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check HLS Therapeutics Inc (HLS) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.93x
HLS Therapeutics Inc's market cap is 1.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $51.13 Million | $54.03 Million | -$874.93K | 0.95x | N/A |
| 2017 | $50.71 Million | $75.08 Million | -$6.10 Million | 0.68x | N/A |
| 2018 | $310.56 Million | $61.41 Million | -$24.81 Million | 5.06x | N/A |
| 2019 | $547.50 Million | $54.16 Million | -$19.55 Million | 10.11x | N/A |
| 2020 | $390.82 Million | $56.11 Million | -$15.33 Million | 6.97x | N/A |
| 2021 | $332.62 Million | $60.01 Million | -$13.12 Million | 5.54x | N/A |
| 2022 | $219.31 Million | $61.47 Million | -$23.60 Million | 3.57x | N/A |
| 2023 | $89.36 Million | $63.07 Million | -$27.53 Million | 1.42x | N/A |
| 2024 | $88.91 Million | $56.62 Million | -$19.66 Million | 1.57x | N/A |
| 2025 | $109.04 Million | $56.47 Million | -$12.65 Million | 1.93x | N/A |
Competitor Companies of HLS by Market Capitalization
Companies near HLS Therapeutics Inc in the global market cap rankings as of September 17, 2026. Review how tangible is HLS Therapeutics Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to HLS Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
HLS Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, HLS Therapeutics Inc's market cap moved from $52.82 Million to $ 92.53 Million, with a yearly change of 5.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$92.53 Million | -15.15% |
| 2025 | CA$109.04 Million | +22.65% |
| 2024 | CA$88.91 Million | -0.51% |
| 2023 | CA$89.36 Million | -59.25% |
| 2022 | CA$219.31 Million | -34.06% |
| 2021 | CA$332.62 Million | -14.89% |
| 2020 | CA$390.82 Million | -28.62% |
| 2019 | CA$547.50 Million | +76.29% |
| 2018 | CA$310.56 Million | +512.41% |
| 2017 | CA$50.71 Million | -0.83% |
| 2016 | CA$51.13 Million | -3.20% |
| 2015 | CA$52.82 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of HLS Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $92.53 Million USD |
| MoneyControl | $92.53 Million USD |
| MarketWatch | $92.53 Million USD |
| marketcap.company | $92.53 Million USD |
| Reuters | $92.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more